Home/Filings/4/0001470831-25-000366
4//SEC Filing

Kumar Neil 4

Accession 0001470831-25-000366

CIK 0001743881other

Filed

Nov 23, 7:00 PM ET

Accepted

Nov 24, 6:46 PM ET

Size

10.9 KB

Accession

0001470831-25-000366

Insider Transaction Report

Form 4
Period: 2025-11-20
Kumar Neil
DirectorChief Executive Officer
Transactions
  • Sale

    Common Stock

    2025-11-20$64.97/sh6,401$415,877248,531 total
  • Sale

    Common Stock

    2025-11-20$65.90/sh14,299$942,361234,232 total
  • Sale

    Common Stock

    2025-11-20$66.71/sh5,456$363,986228,776 total
Holdings
  • Common Stock

    (indirect: By Trust)
    795,686
  • Common Stock

    (indirect: By Trust)
    4,598,447
Footnotes (5)
  • [F1]This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025.
  • [F2]Represents the weighted average sale price of the shares sold from $64.49 to $65.48 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
  • [F3]Represents the weighted average sale price of the shares sold from $65.49 to $66.48 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
  • [F4]Represents the weighted average sale price of the shares sold from $66.49 to $67.18 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
  • [F5]The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.

Issuer

BridgeBio Pharma, Inc.

CIK 0001743881

Entity typeother

Related Parties

1
  • filerCIK 0001742485

Filing Metadata

Form type
4
Filed
Nov 23, 7:00 PM ET
Accepted
Nov 24, 6:46 PM ET
Size
10.9 KB